Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females ≥ 19 years and ≤ 80 years old undergoing isolated CABG~2. Females of child-bearing age must have a negative pregnancy test at enrollment~Exclusion Criteria:~1. Patients undergoing combined valve or aortic surgeries~2. Patients requiring oral anticoagulant therapy on discharge that cannot be stopped (e.g. atrial fibrillation with CHADS2 score ≥ 2, pulmonary embolism, deep venous thrombosis)~3. Known allergy or intolerance to aspirin, clopidogrel or ticagrelor~4. Patients with active bleeding or history of bleeding diathesis~5. Patients with previous intracranial hemorrhage at any time, or ischemic stroke within 14 days~6. Patients with severe liver disease (e.g. ascites or signs of coagulopathy)~7. Patients with pre-operative or persistent post-operative Type 2 second-degree AV block, or 3rd degree AV block, without a permanent pacemaker~8. Patients with end-stage renal failure requiring dialysis~9. For patients enrolled in the CT angiography substudy, renal dysfunction with eGFR \< 50 ml/min is an exclusion criteria

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice daily. Study drug will be started within 48 hours of CABG.
- ticagrelor 90 mg (Type: ACTIVE_COMPARATOR): Taken twice daily. Study drug will be started within 48 hours of CABG.

Based on this trial design, predict the completion outcome and termination type (if applicable).